ArticleCureus2025
A National Cancer Database Study on the Demographic, Prognostic, and Socioeconomic Factors Affecting Survival in Adenocarcinoma in Villous Adenoma.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeAdenocarcinoma in villous adenoma is a rare malignancy arising from adenomatous polyps with a high villous content. This study aims to identify the demographic, prognostic, and socioeconomic factors influencing overall survival using data sourced from the National Cancer Database (NCDB).
methodsPatients diagnosed with adenocarcinoma in villous adenoma were identified from the NCDB between 2004 and 2020. Kaplan-Meier curves, multivariable Cox proportional hazards models, life tables, and log-rank tests were used to assess the impact of variables such as age, sex, NCDB tumor stage, Charlson-Deyo (CD) comorbidity score, primary therapies, adjuvant therapies, and socioeconomic factors on survival.
resultsThis cohort of 19,120 patients with adenocarcinoma in villous adenoma revealed multiple statistically significant factors affecting survival. Demographically, males had an 18% higher risk of mortality compared to females (hazard ratio (HR): 0.82; 95% confidence interval (CI): 0.79-0.86; p<0.001), older age (76-100 age group, five years: 45.3%; 10 years: 20.7%; p<0.001) correlated with poorer outcomes, and Black patients had a 22% increased mortality risk relative to White patients (HR: 1.22; 95% CI: 1.14-1.30; p<0.001). Socioeconomically, patients in lower-income brackets (<$46,277 vs. ≥$74,063, HR: 0.88; 95% CI: 0.82-0.94; p<0.001) and those with Medicare or Medicaid insurance faced increased mortality risks compared to those with private insurance (Medicare, HR: 1.26; 95% CI: 1.19-1.33; p<0.001; Medicaid, HR: 1.57; 95% CI: 1.41-1.74; p<0.001). Disease and comorbidity factors showed that higher CD comorbidity scores (10-year survival: 25.9% for CD 2; 17.8% for CD 3; p<0.001) and stage IV disease (HR: 9.23; 95% CI: 8.32-10.24; p<0.001) were associated with poorer outcomes. Regarding treatment, primary radiation increased mortality risk by 24% (HR: 1.24; 95% CI: 1.15-1.33; p<0.001), while neoadjuvant radiation and adjuvant chemotherapy decreased mortality risk by 39% (HR: 0.61; 95% CI: 0.54-0.69; p<0.001) and 26% (HR: 0.74; 95% CI: 0.68-0.81; p<0.001), respectively.
conclusionAdenocarcinoma in villous adenoma outcomes is influenced by age, sex, race, NCDB cancer stage, comorbidities, and treatment type. Surgical intervention remains the primary treatment and confers improved survival outcomes, emphasizing the importance of early detection and treatment. Further research, including prospective studies, is needed to validate these findings, investigate the mechanisms underlying observed disparities, and optimize treatment strategies, particularly the role of adjuvant therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.